An Unbiased View of BMS-199264 hydrochloride
All enrolled clients who received at least one particular dose of zosuquidar or placebo throughout induction ended up monitored with the incidence of adverse gatherings (439 sufferers, 219 on zosuquidar and 210 on placebo). The commonest adverse events have been connected to the duration of extended and significant myelosuppression as is predicted